Tectonic Therapeutic Inc
TECX
NASDAQ
Biotechnology
$34.91
USD
+0.93 (+2.74%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $685.01M
Volume 84.2K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-85.79M
TTM
-30.0%
YoY
Operating Cash Flow
$-72.14M
TTM
-12.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 5.1 | 5.0 | 5.2 | 6.4 | 6.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 22.3 | 21.9 | 21.5 | 27.3 | 24.2 |
Operating Income | -22.3 | -21.9 | -21.5 | -27.3 | -24.2 |
EBITDA | -22.0 | -21.5 | -21.2 | -27.0 | -23.9 |
Other Income / Expense | -0.0 | -0.0 | -0.0 | -0.1 | -0.0 |
Total Other Income / Expense | 3.3 | 2.9 | 2.5 | 2.1 | 2.0 |
Income Before Income Taxes | -19.0 | -19.0 | -19.0 | -25.2 | -22.2 |
Income Taxes | 1.0 | 0.0 | 0.3 | 0.0 | 0.1 |
Net Income | -20.0 | -19.0 | -19.2 | -25.2 | -22.3 |
Consolidated Net Income / Loss | -20.0 | -19.0 | -19.2 | -25.2 | -22.3 |
Net Income Attributable to Common Shareholders | -20.0 | -19.0 | -19.2 | -25.2 | -22.3 |
Basic EPS | -$1.07 | -$1.02 | -$1.03 | -$1.34 | -$1.18 |
Diluted EPS | -$1.07 | -$1.02 | -$1.03 | -$1.34 | -$1.18 |
Basic Shares Outstanding | 18.7M | 18.7M | 18.7M | 18.8M | 19.0M |
Diluted Shares Outstanding | 18.7M | 18.7M | 18.7M | 18.8M | 19.0M |